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ess: ling-pei.ho@imm.oSummary It is now widely accepted that augmented levels of fractional exhaled
nitric oxide (FeNO) reflect airway inflammation and the methodology has been
optimised for potential clinical use. We were interested in investigating whether this
measurement can be used as a tool to screen and identify school children with
asthma. To do this, FeNO was measured using an on-line single exhalation analyser in
368 children aged 8–10 years in six Oxfordshire primary schools, by two investigators
blinded to the disease status of the children. The children were then categorised
into ‘normal’, ‘atopic asthma’, ‘non-atopic asthma’ and ‘atopy only’ groups,
according to their responses to the ISAAC questionnaire and perusal of the children’s
medical records kept by their family practitioners. Increased levels of FeNO were
found in ‘atopic asthmatic’, ‘non-atopic asthmatics’ and ‘atopic only’ groups
(median values of 24.4, 7.8 and 15.3 ppb, respectively, compared to normal controls’
of 6.9 ppb). Levels were increased in atopic children regardless of whether they had
asthma and were significantly higher than non-atopic asthmatics. We conclude that
FeNO measurement is not a useful tool for identifying children with asthma in the
community, as increased levels did not discriminate between those with asthmatic
and atopic symptoms.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The prevalence of asthma in children has increased
dramatically in the last three decades.1 Environ-Elsevier Ltd. All rights reserv
l Institute of Molecular
nit, The John Radcliffe,
l.: +44 1865 222 334; fax:
x.ac.uk (L.-P. Ho).mental influences such as an increase in air
pollution, dietary changes, and decreased exposure
to immune stimulating diseases in childhood (the
‘hygiene hypothesis’) are among several hypoth-
eses put forward to explain this trend.2 In parallel
with this there is a growing need for a simple and
reliable method to identify children with, or those
who are at risk of developing, asthma. Due to
its many phenotypic expressions through the
course of childhood and often non-specific clinicaled.
ARTICLE IN PRESS
A. Prasad et al.168manifestations, diagnosing asthma in childhood
remains a clinical challenge. In the last decade a
few non-invasive methods of measuring airway
inflammation have been proposed as possible
methods to aid the clinical diagnosis of this
condition. One of them, fractional exhaled nitric
oxide (FeNO), has been the subject of particular
investigations. Nitric oxide is synthesised by in-
flamed airway epithelial cells (e.g. in asthma) and
can be measured in orally exhaled air.3 Since it was
first used, numerous modifications have been made
to improve the measurement of FeNO as a potential
clinical tool. There is now sufficient evidence that
increased FeNO can be used as a measure of
response to corticosteroid treatment,4–6 that it
correlates with eosinophilic inflammation in adults
and children,7–9 and bears a positive relationship
with airway hyperresponsiveness and response to
bronchodilators.10 However, its role as a diagnostic
tool is less well established11 and it is unclear if it
can be used independently to identify children with
asthma or those who might benefit from fuller
investigation for this diagnosis. Some studies
suggest this might be possible.12,13 We propose
that if this were the case, then one potential use
would be in the screening of school children in the
community for early diagnosis of asthma. We have
investigated if this is feasible by measuring FeNO in
a large cohort of children from six different primary
schools representing a cross section of social
classes, and then assessing if high levels of FeNO
identified children with asthma.Methods
Study population and design
This was a cross-sectional prospective study. School
children aged 8–10 years were recruited from six
primary schools in an Oxfordshire town in England
(Abingdon). Two studies were conducted. In the
first study, 47 children aged 7–9 years had FeNO
levels measured in the same month (June) on two
consecutive years with the aim of: (1) examining
the feasibility of measuring FeNO in the community
and in a large cohort of children and (2) to provide
data to examine the long term stability (biological
variability) of FeNO measurements. We have
already established the technical reproducibility
in previous studies.14 Having determined that the
study was feasible and FeNO measurements were
biologically stable, we proceeded to the second
study. Here FeNO levels were measured in 378
children aged 8–10 years by two investigators whowere blinded to the children’s disease status. The
schools were chosen to represent the spread of
economic and social background of this town. All
school children aged 8–10 years in each school were
invited to participate in the study. Children with
signs or symptoms of a respiratory tract infection
within 4 weeks of the study were excluded.
The diagnoses of asthma and/or atopy were
made by interpreting the ISAAC (International
Study of Asthma and Allergies in Childhood)
questionnaire15 in conjunction with the child’s
medical records. This questionnaire was distributed
to the parents of the children a week before
exhaled NO measurement and collected after all
the FeNO levels had been tabulated. The responses
(see below) were used to categorise the children to
four groups—‘normal’, ‘asthmatic, no atopy’,
‘asthmatic, atopy’ and ‘atopy, no asthma’. In
addition, the medical notes kept by the family
practitioners of these children were perused and
the diagnosis of ‘asthma’, ‘hay fever’ and ‘eczema’
were noted, together with the use of inhaled or
oral corticosteroids.
The parents of every child provided informed
assent for their child. The study was approved by
the Oxford Research Ethics Committee.Fractional exhaled nitric oxide measurement
FeNO was measured using a single exhalation
method with the Logan LR2000 analyser (Logan
Research, Bromley, Kent, UK). The child was
coached to exhale slowly from total lung capacity
(TLC), without prior breath holding while observing
the screen to maintain a steady expiratory flow.
Mouth pressure and flows were kept at 10 cm H2O
and 50ml/s, respectively. FeNO values were re-
corded from the best-fit plateau during steady
exhalation. An average of three recordings were
made and the mean FeNO of these recordings was
taken as the representative level.
Height, FEV1 and FVC were also recorded.
Spirometry was measured with a hand held spirom-
eter (MicroSpirometer MS01, MicroMedical Ltd,
Rochester, Kent, UK) after the FeNO measurement,
as FEV1 manoeuvre has been shown to affect
subsequent FeNO levels.16Diagnosis of asthma and atopy
From the ISAAC questionnaire, a diagnosis of
current or active asthma was made if there was a
positive response to the question of whether there
was wheezing or whistling in the chest or being
wheezy during or after exercise. Having a dry cough
ARTICLE IN PRESS
Exhaled NO as a screening tool for asthma 169at night without any other symptoms was not
interpreted as asthma.
For atopy the questions were divided into those
for hay fever (allergic rhino-conjunctivitis) and
those for atopic eczema. To diagnose hay fever the
child must have had problems with sneezing or a
runny or blocked nose accompanied by itchy and
watery eyes mainly in the summer months. For
eczema, the child should have had a recurrent itchy
rash affecting one of the characteristic sites.
Having either hay fever or atopic eczema counted
the child as being atopic. We took the child’s
lifetime prevalence of atopic symptoms to deter-
mine if the child was atopic or not.
Case notes for each child, kept by the family
practitioner, were perused by a medically qualified
investigator for the diagnosis of asthma, hay fever
and eczema. Inhaled medications were noted.
Where there were discrepancies between the
questionnaire and the family physician’s notes,
the diagnosis from the latter was used.Statistical analysis
Normality of distribution was determined using the
Kolmogorov-Smirnov test. As FeNO levels showed a
non-parametric distribution, they were reported as
medians with inter-quartile ranges. Statistical
differences between asthmatics, atopics and nor-
mals were analysed using Kruskal–Wallis ANOVA on
ranks test, assessing the group as a whole. Having
determined that there was a statistical difference
in median values between the groups using this
method, groups that differ from others were
isolated using a multiple comparison method
(Dunn’s Method). Correlations between FeNO and
FEV1, FVC and height were assessed using the
Spearman Rank Order correlation test and between
FeNO and gender with Mann Whitney Rank Sum Test.
Reproducibility of FeNO from one year to the next
was analysed using Spearman Rank Order correla-
tion test and calculation of threshold changes from
one year to the next (illustrated in Fig. 2).Table 1 Range of FeNO levels for each group of childre
n FeNO range (p
Normal 209 1.7–64.2
Non-atopic asthma 40 3.6–71.2
Atopic asthma 45 2.7–80.6
Atopy alone 74 3.7–90.5
FeNO levels were significantly higher in asthmatics, atopic asthm
significantly different between each other expect between ‘atopy
on ranks and Po0:05 by Dunn’s method of multiple comparison).Results
Characteristics of study population and
distribution of FeNO
In study 1, all 47 recruited children performed the
procedures optimally and there were no practical
or logistic problems with managing the study. FeNO
levels were distributed non-parametrically in this
cohort as a whole.
In study 2, of the 378 children that were
recruited, one child was unable to perform the
FeNO manoeuvre. Questionnaires from nine chil-
dren were not returned. These subjects were
excluded from analysis. The study population
therefore comprised 368 children, 177 females
and 191 males. The range of FeNO in the whole
population was 1.7–90.5 ppb. The greatest spread
of values was observed in the atopic group and
least in the normal group (Table 1).
The age range was 8.1–10.8 years with a mean of
9.1 years. There was no statistically significant
difference between these age groups. FeNO values
were non-parametrically distributed in the whole
population (Fig. 1) and also within each group of
normal, atopy, asthma and atopic asthma.
From the distribution in the normal (asympto-
matic) children, we determined the normal range
to be the 95% confidence level of the median. This
was similar (as expected) to a separate assessment
where the values from the normal children were
log10 transformed, and then taking the mean of this
72 SD as the normal range. From these analyses,
the normal range was set as 4.2–11.2 ppb. We
considered values greater than 11.2 ppb as raised.
Using this criteria, 43 (21%) of asymptomatic
children had raised exhaled NO levels.Biological variability of FeNO
From study 1, we observed no significant difference
between FeNO levels in the first year and in the
second year (median of FeNO year 1: 10.2 ppb, I.Qn.
pb) Median FeNO(ppb) I.Q range
6.9 5.2–10.2
7.8 5.9–27.6
24.4 11.6–34.0
15.3 10.1–29.4
atics and atopics compared to normal. FeNO levels were also
alone’ and ‘atopic asthma’ (Po0:001 by Kruskal-Wallis ANOVA
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Figure 2 Correlation between FeNO levels taken in the
first year and repeated in the same month in the second
year for 47 school children (study 1). There was
significant correlation, calculated by Spearman Rank
Order Test. The vertical line denote the median value
for year 1 and horizontal line, the median value for year
2. Therefore the values in the upper right and lower left
boxes or ‘quadrants’ represent values that had remained
stable in the intervening year. Values in the lower right
box moved from higher than median values in the first
year to lower than median values in the second year and
vice versa in upper left box.
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Figure 1 FeNO levels in normal (asymptomatic) children
(n ¼ 209) (from study 2); demonstrating a negatively
skewed normal distribution.
A. Prasad et al.170range 5.5–15.2 vs. FeNO year 2: 11.4 ppb, I.Q range
5.7–25.1; Mann Whitney Rank Sum test, P ¼ 0:13).
Correlation co-efficient between the two years’
readings showed a statistically significant positive
correlation (r ¼ 0:7; Po0:001) (Fig. 2). Therefore,
those children with high FeNO in year 1 also had
high FeNO in year 2. We also divided the graph into
four ‘quadrants’ or boxes, the lines of division
being the median value for that year (see Fig. 2).
From this the upper right and upper left boxes
represent ‘high’ values for year 2, here assigned as
values greater than the median; and the upper
right and lower right boxes represent ‘high’ values
for year 1. From this analysis, it is seen that only 7
of 47 subjects crossed from ‘low’ to ‘high’ or vice
versa between the 2 years. It should be noted that
this is a relatively stringent assessment of ‘high’
and ‘low’ FeNO threshold, which ignored the
normal range around the median that we used as
our biological range (see paragraph above).Correlation with lung function, height
and sex
As FeNO may correlate with the NO producing
surface area in the airways which is related to FVC
and height; and with FEV1 itself,
17 we assessed the
relationship between these parameters and FeNO
in normal children.
FEV1 and FVC ranged from 1.0 to 2.6 l/min and
1.4–3.3 l, respectively, in the normal group. Analy-
sis using the Spearman Rank Order Correlation
Coefficient showed no correlation between FeNO
levels and FEV1 and FVC (correlation coefficients:
0.08 and 0.04, P ¼ 0:315 and 0.51, respectively,Fig. 3). Further analysis of the whole study
population including those with asthmatic and
atopic symptoms also showed no evidence of
statistically significant correlation.
There was no correlation between FeNO and
height (P ¼ 0:16) or FeNO and gender (P ¼ 0:33)
(Spearmann’s Rank Order correlation test and
Mann-Whitney Rank Sum test, respectively).
FeNO in different ‘diagnostic’ groups
209/368 (57%) children were categorised as normal,
40/368 (11%) as non-atopic asthmatics, 45 (12%) as
atopic asthma and 74/368 (20%) as atopic alone
(Fig. 4). There were only eight discrepancies in
diagnosis of asthma between the physicians’ case
records and the ISAAC questionnaire (more in the
former; and these were taken as the ‘correct’
diagnosis). FeNO was significantly higher in atopic
children regardless of whether they had asthma
compared to normals (Table 1). Post-hoc assess-
ment (Dunn’method) after Kruskal-Wallis analysis
of the four groups showed significant differences
between all groups except ‘atopic asthmatic’ and
‘atopic only’ groups (Table 1).
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Figure 4 FeNO levels in children divided into various
groups according to ISAAC questionnaire and medical
case notes. Horizontal bar represents median values for
each group. The levels were significantly increased in all
groups compared to normal (see Table 1); and signifi-
cantly different between all groups except ‘atopic
asthmatic’ and ‘atopic only’ groups. The two dashed
horizontal lines represent the range for normal values of
FeNO (see text, under ‘Results’ for calculation).
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Figure 3 Graphs showing relationship between FeNO
levels and FEV1 and height of children. No significant
relationship was noted. The same results were observed
for FeNO and FVC.
Exhaled NO as a screening tool for asthma 171The asthmatic group was further divided accord-
ing to whether the child was taking an inhaled or
oral corticosteroid. No child in the ‘atopic only’ or
‘normal’ groups was on inhaled corticosteroids; and
none at all were on oral corticosteroids. 15/40
(37.5%) non-atopic asthmatics and 23/45 (51%)
atopic asthmatics were on an inhaled corticoster-
oid. Excluding children on corticosteroids, all the
above findings still held true. Median FeNO levels in
asthmatic children on inhaled corticosteroids
(n ¼ 47) were 14.2 ppb and in those not on inhaled
corticosteroids (n ¼ 38) were 21.7 ppb. These
were not statistically different (P ¼ 0:4); but the
lower median values in those children on inhaled
corticosteroids is in keeping with data from other
workers.Discussion
In recent years a few studies have begun examining
the potential use of exhaled NO as a diagnostic or
screening tool for disease (asthma or primary
ciliary dyskinesia) in children.11–13,18 Most studies
have recruited children from paediatric specialist
clinics and examined the correlation of FeNO and
disease within an experimental setting. While FeNO
is increased in asthmatic children, their diagnostic
utility is unclear. Narang and colleagues11 found
FeNO measurements not to be useful in distinguish-
ing between cystic fibrosis and bronchiectasis, but
agreed that asthmatic children had higher levels of
FeNO. Malmberg et al.13 recruited children from
their paediatric physiology clinic and compared
whether exhaled NO levels or respiratory function
assessments corresponded more sensitively with
the final clinical diagnosis of asthma in a group of
asthmatic pre-school children. They observed
superiority in exhaled NO measurements in this
regard. Our study is the first to report use of this
method prospectively as a screening tool in
children and within a potentially ‘real’, non-
laboratory setting in the community. Here, we
found that although higher exhaled NO levels were
seen in children with asthmatic symptoms, this was
also the case for individuals with atopy. Therefore,
it did not discriminate between children with
asthma and those with atopic symptoms alone.
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method for identifying asthma. There was also no
statistically significant difference in the degree of
elevation in exhaled NO comparing children in the
atopic only and atopic-asthmatic groups, although
the median is higher in the atopic-asthmatic
groups. This is not entirely surprising as we and
others have already shown that exhaled NO is
increased in atopic adults regardless of whether
they had a formal diagnosis of asthma.19–21 Our
findings also concur with a similar study on
Norwegian adolescents.22
The exact mechanism for the association of
increased FeNO and atopy is unclear; but it is
becoming evident that NO production correlates
more specifically with airway inflammation where
eosinophilia and clinical atopic features dominate.
Recent studies examining bronchoalveolar lavage
(BAL) fluid from children may provide a unifying
explanation. Eosinophilic cationic proteins are
significantly higher in BAL fluid collected from
atopic asthmatic children during asymptomatic
periods compared to controls23 suggesting that
eosinophils are active in these children even in
the absence of ongoing symptoms.24 Does this
suggest that atopics with increased FeNO levels
could have a higher risk of developing asthma? It is
apparent from our study that not all children with
atopic symptoms have increased FeNO levels. From
our calculated normal range, a greater number of
atopic asthmatics had ‘high’ levels of FeNO (71%
with FeNO levels greater than 11.9 compared 65%
in atopic alone group). Atopy in children is the only
robust factor associated with increased risk of
persistence and severity of asthma in later child-
hood and adulthood.25,26 Patients with history of
asthma or wheezy bronchitis by age of 16 years
were twice as likely to report episodes of wheezing
in the past year (at the age of 33 years) if they had
also experience hay fever, allergic rhinitis and
eczema as a child.25 It is possible to hypothesise
that a combination of atopy and increased exhaled
NO levels may pick out those children that may be
at greater risk of having persistent asthmatic
symptoms in adulthood. This suggestion can only
be explored in a longitudinal study.
The spread of exhaled NO levels in children
without asthmatic or atopic symptoms was inter-
esting. This showed that normal healthy children
had levels ranging from 1.7 to 64.2 ppb; with a
clear tail of ‘high’ NO producers in the distribution
profile. It is not possible to tell whether these
asymptomatic high producers fall into a group that
may be at an increased risk of developing of asthma
in adulthood, whether this is a precursor to atopy
or if these are normal individuals who simply havehigh levels of NO with no clinical sequelae. We had
excluded upper respiratory tract infections from
these children and our pilot reproducibility work
demonstrated that those patients with high ex-
haled NO levels remained high the next year and
vice versa. Again, only a longitudinal study would
provide answers to these questions. The spread
aside, the mean and median levels were compar-
able to other studies using similar flow rates and
type of analyser.27
In terms of methodology, we did not encounter
any major problems with measuring FeNO on a
large scale in the community. Most children found
the experience easy, required little coaxing to
complete it successfully and the procedure was
performed within 5 minutes per child. The only
unexpected event was the build up of water vapour
in the first part of the collection tube attached to
the analyser. This, we detected during our first
study and we subsequently ensured that this was
eradicated every few children by removing the
collection tube and flushing it with an air pump.
Our use of 10 cm H2O for mouth pressure and 50ml/
s flow were determined in pilot studies. We chose a
mouth pressure that did not allow nasal escape and
one which 6–9 year olds could tolerate with ease.
This was also the flow rate validated independently
by other workers.28,29
The combined use of the ISAAC questionnaire and
family physician’s diagnosis for categorisation to
asthma and atopy provided a more secure method
of diagnosing the condition than the use of the
questionnaire alone. The ISAAC questionnaire was
used in our study as it provided the best validated
questionnaire method.14 Several methods exist for
identifying asthma in the community. Most workers
acknowledge that current methods only identify
asthmatic or atopic symptoms and an accurate
diagnosis is necessarily a clinical one involving full
individual assessment of the child. Surprisingly,
there was a slight ‘over-call’ of asthma from the
physician’s case records. This could be explained by
a closer relationship between the family practi-
tioners and their patients in this close knit town,
than would be seen in bigger cities with higher
turnover of patients.
In summary, our study shows that FeNO measure-
ment is not a useful tool for identifying children
with asthma in the community, as increased levels
did not discriminate between those with asthmatic
and atopic symptoms. However, increased exhaled
NO levels were seen in a greater proportion of
atopic asthmatic than atopic only children, and
some children with no symptoms (normal) were
identified as having high FeNO levels. This raises
the possibility that increased NO levels may yet
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